Etoposide for epidemic Kaposi's sarcoma: a phase II study.
Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.
Bakker
P J
PJ
Division of Medical Oncology, University of Amsterdam, The Netherlands.
Danner
S A
SA
Lange
J M
JM
Veenhof
K H
KH
D000328:Adult; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D005047:Etoposide